ImmunityBio, Inc.

IBRX

$2.50

Name : ImmunityBio, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $2,363,136,512.00

EPSttm : -0.48

ImmunityBio, Inc.

$2.50

1.19%

$0.03

Float Short %

Margin Of Safety %

Put/Call OI Ratio

0.24

EPS Next Q Diff

-0.01

EPS Last/This Y

0.15

EPS This/Next Y

0.16

Price

2.5

Target Price

10.2

Analyst Recom

Performance Q

-10.39

Relative Volume

1.05

Beta

0.18

Ticker: IBRX

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-08	IBRX	2.4	0.25	0.24	246303
2025-09-09	IBRX	2.58	0.25	0.20	248521
2025-09-10	IBRX	2.57	0.25	0.09	251001
2025-09-11	IBRX	2.56	0.25	0.09	251726
2025-09-12	IBRX	2.59	0.25	0.05	254009
2025-09-15	IBRX	2.66	0.25	0.10	255290
2025-09-16	IBRX	2.85	0.24	0.16	257268
2025-09-17	IBRX	2.76	0.2435957505809	0.051601423487544	260108
2025-09-18	IBRX	2.86	0.24	0.27	260033
2025-09-19	IBRX	2.72	0.24	0.16	262000
2025-09-22	IBRX	2.66	0.23	0.71	236313
2025-09-23	IBRX	2.59	0.24	0.35	239785
2025-09-24	IBRX	2.51	0.24	0.47	243876
2025-09-25	IBRX	2.46	0.24	0.69	244968
2025-09-26	IBRX	2.54	0.25	0.36	247798
2025-09-29	IBRX	2.57	0.25	0.42	249972
2025-09-30	IBRX	2.45	0.25	0.18	250953
2025-10-01	IBRX	2.48	0.25	0.27	253243
2025-10-02	IBRX	2.5	0.25	0.15	259316
2025-10-03	IBRX	2.54	0.25	0.16	260419
2025-10-06	IBRX	2.53	0.24	0.12	262470
2025-10-07	IBRX	2.51	0.24	0.14	264015
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-08	IBRX	2.41	12.5	43.1	-0.47
2025-09-09	IBRX	2.58	12.5	31.1	-0.47
2025-09-10	IBRX	2.58	12.5	43.1	-0.47
2025-09-11	IBRX	2.59	16.7	42.4	-0.44
2025-09-12	IBRX	2.59	16.7	44.2	-0.44
2025-09-15	IBRX	2.75	16.7	33.3	-0.44
2025-09-16	IBRX	2.81	16.7	39.2	-0.44
2025-09-17	IBRX	2.76	16.7	47.4	-0.44
2025-09-18	IBRX	2.85	16.7	37.9	-0.44
2025-09-19	IBRX	2.72	16.7	51.9	-0.44
2025-09-22	IBRX	2.67	16.7	47.9	-0.44
2025-09-23	IBRX	2.58	16.7	50.0	-0.44
2025-09-24	IBRX	2.51	16.7	49.8	-0.44
2025-09-25	IBRX	2.46	16.7	46.7	-0.44
2025-09-26	IBRX	2.54	16.7	37.9	-0.44
2025-09-29	IBRX	2.57	16.7	41.7	-0.44
2025-09-30	IBRX	2.45	16.7	52.0	-0.44
2025-10-01	IBRX	2.48	16.7	41.6	-0.44
2025-10-02	IBRX	2.49	16.7	42.7	-0.44
2025-10-03	IBRX	2.54	16.7	41.3	-0.44
2025-10-06	IBRX	2.53	16.7	41.7	-0.44
2025-10-07	IBRX	2.50	16.7	46.0	-0.44
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-08	IBRX	0.00	144.01	76.45
2025-09-09	IBRX	0.00	144.01	76.45
2025-09-10	IBRX	0.00	144.01	76.45
2025-09-11	IBRX	0.00	144.01	76.59
2025-09-12	IBRX	0.00	144.01	76.59
2025-09-15	IBRX	0.00	144.49	76.59
2025-09-16	IBRX	0.00	144.49	76.59
2025-09-17	IBRX	0.00	144.49	76.59
2025-09-18	IBRX	0.00	144.49	76.59
2025-09-19	IBRX	0.00	144.49	76.59
2025-09-22	IBRX	0.00	144.51	76.59
2025-09-23	IBRX	0.00	144.51	76.59
2025-09-24	IBRX	0.00	144.51	76.59
2025-09-25	IBRX	0.00	144.51	86.00
2025-09-26	IBRX	0.00	144.51	86.00
2025-09-29	IBRX	0.00	144.51	86.00
2025-09-30	IBRX	0.00	144.51	86.00
2025-10-01	IBRX	0.00	144.51	86.00
2025-10-02	IBRX	0.00	144.51	86.00
2025-10-03	IBRX	0.00	144.51	86.00
2025-10-06	IBRX	0.00	24.14	86.00
2025-10-07	IBRX	0.00	24.14	86.00
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.1

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

-0.11

Insider Transactions

Institutional Transactions

24.14

Beta

0.18

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

93.9

Max Drawdown 5-Year %

Target Price

10.2

P/E

Forward P/E

PEG

P/S

41.75

P/B

P/Free Cash Flow

EPS

-0.49

Average EPS Est. Cur. Y

-0.44

EPS Next Y. (Est.)

-0.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-648.57

Relative Volume

1.05

Return on Equity vs Sector %

39.1

Return on Equity vs Industry %

52.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

ImmunityBio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 685

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

stock quote shares IBRX – ImmunityBio, Inc. Stock Price stock today

news today IBRX – ImmunityBio, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch IBRX – ImmunityBio, Inc. yahoo finance google finance

stock history IBRX – ImmunityBio, Inc. invest stock market

stock prices IBRX premarket after hours

ticker IBRX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: IBRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y